Research into a fatal childhood brain cancer has stalled for a full year following the sudden termination of a federal consortium.
The National Cancer Institute altered web pages regarding the Pediatric Brain Tumor Consortium as part of the Trump administration’s moves affecting federal research funding. When the government did not renew the consortium’s $4 million annual grant, researchers had to archive decades of data and pause active clinical trials.
Families affected by diffuse intrinsic pontine glioma and other rare pediatric brain tumors expressed deep frustration over the halt. Amanda Schecter told The New York Times about their experience. When Ryleigh Schecter answered the front door to her home, she wore an oversized lavender bow matching the stripes on her shirt, telling visitors that rainbow is her favorite color.
At St. Jude Children’s Research Hospital, 27 years of research data on more than 2,000 children with rare brain tumors had to be archived. Several clinical trials investigating novel therapies were also interrupted by the closure.
One affected study was a Phase 1 trial exploring the safety of CAR-T cell therapy in patients with ependymoma, led by researchers at Texas Children’s Hospital in Houston and designated as PBTC-059. Another trial investigating whether cerebral spinal fluid could replace invasive brain biopsies was closed entirely.
Parent advocacy groups mobilized immediately following the cancellation. A bipartisan group from New York, including Representative Mike Lawler, called on Health and Human Services Secretary Robert F. Kennedy Jr. to reverse the decision.
Earlier coverage: Cambridge Researchers Find Leukaemia Mutations Can Start in Youth